| Also known as |
GW-501516, Cardarine |
| Blood pressure |
No significant impact |
| Chemical name |
{4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid |
| Dosage (medical) |
Not medically approved for therapeutic use |
| Dosage (sports) |
10-20 mg per day |
| Effects |
Increased endurance, fat loss, improved lipid profile |
| Formula |
C21H18F3NO3S2 |
| Half-life |
16-24 hours |
| Hepatotoxicity |
Yes, potential liver toxicity |
| Lab Test |
Detection in blood and urine tests |
| Main action |
Enhances fatty acid metabolism |
| Side effects |
Potential carcinogenic effects, liver toxicity, possible development of other cancers |
| Storage conditions |
Store at room temperature, protect from light and moisture |
| Substance class |
PPARОґ receptor agonist |
| Trade name |
Not available as a legally approved drug |
| Use in sports |
Banned by major sports organizations |
| Water Retention |
No |
| Release form |
Packaging (60 capsules) |
| Manufacturer |
Magnus Pharmaceuticals |
| Packing |
Capsule |
